Publication
Glutaryl-CoA Dehydrogenase Misfolding in Glutaric Acidemia Type 1.
Journal Paper/Review - Aug 24, 2023
Barroso Madalena, Gertzen Marcus, Puchwein-Schwepcke Alexandra F, Preisler Heike, Sturm Andreas, Reiss Dunja D, Danecka Marta K, Muntau Ania C, Gersting Søren W
PubMed
Doi
Contact
Citation
Type
Journal
Publication Date
Issn Electronic
Brief description/objective
Glutaric acidemia type 1 (GA1) is a neurotoxic metabolic disorder due to glutaryl-CoA dehydrogenase (GCDH) deficiency. The high number of missense variants associated with the disease and their impact on GCDH activity suggest that disturbed protein conformation can affect the biochemical phenotype. We aimed to elucidate the molecular basis of protein loss of function in GA1 by performing a parallel analysis in a large panel of missense variants using different biochemical and biophysical methodologies. Thirteen GCDH variants were investigated in regard to protein stability, hydrophobicity, oligomerization, aggregation, and activity. An altered oligomerization, loss of protein stability and solubility, as well as an augmented susceptibility to aggregation were observed. GA1 variants led to a loss of enzymatic activity, particularly when present at the N-terminal domain. The reduced cellular activity was associated with loss of tetramerization. Our results also suggest a correlation between variant sequence location and cellular protein stability ( < 0.05), with a more pronounced loss of protein observed with variant proximity to the N-terminus. The broad panel of variant-mediated conformational changes of the GCDH protein supports the classification of GA1 as a protein-misfolding disorder. This work supports research toward new therapeutic strategies that target this molecular disease phenotype.